title: Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
authors.affiliation: Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.
authors.forename: H H
authors.initials: HH
authors.lastname: van Ojik
authors.forename: R
authors.initials: R
authors.lastname: Repp
authors.forename: G
authors.initials: G
authors.lastname: Groenewegen
authors.forename: T
authors.initials: T
authors.lastname: Valerius
authors.forename: J G
authors.initials: JG
authors.lastname: van de Winkel
mesh_terms: D000328:Adult; D000368:Aged; D018033:Antibodies, Bispecific / Q000097:blood / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*; D011994:Recombinant Proteins
chemical_list: D018033:Antibodies, Bispecific; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor; D018719:Erb-b2 Receptor Tyrosine Kinases; D017452:Receptors, IgG; D011994:Recombinant Proteins